National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 36 of 41
HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs
NCT00001103
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
NCT00000803
An HIV Vaccine Preparedness Study
NCT00000915
A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT
NCT00001032
A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.
NCT00000855
Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
NCT00000630
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
NCT00000802
A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
NCT00000757
A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
NCT00000775
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
NCT00000641
A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
NCT00000688
Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals
NCT00000684
Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
NCT00000636
Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women
NCT00096694
Increasing HAART-Induced Immune Restoration With Cyclosporine
NCT00031070
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease
NCT00000696
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex
NCT00000675
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
NCT00015652
A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma
NCT00000763
Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs
NCT00001083
A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection
NCT00000702
A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
NCT00001060
A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease
NCT00000662
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
NCT00000872
The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV
NCT00001034
HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol
NCT00000799
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
NCT00000939
Carotid Artery Thickness in HIV Infected and Uninfected Adults
NCT00007319
Effect of Interleukin-2 on HIV Treatment Interruption
NCT00015704
Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
NCT00001014
A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection
NCT00000812
A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past
NCT00001029
HIV Prevention Counseling for Men Who Have Sex With Men
NCT00000931
An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3
NCT00000747
Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
NCT00000977
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
NCT00001087
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
NCT00000796
A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children
NCT00000637
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
NCT00014937
Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma
NCT00000695
An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex
NCT00000672
The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients
NCT00000860
A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection
NCT00000750
Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus
NCT00006643
Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma
NCT00000660
A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients
NCT00000655
A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA
NCT00000840
The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)
NCT00076518
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
NCT00001043
Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection
NCT00000959
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.